Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors - PubMed (original) (raw)
. 2007 Dec;60(6):1409-10.
doi: 10.1093/jac/dkm372. Epub 2007 Oct 3.
- PMID: 17913723
- DOI: 10.1093/jac/dkm372
Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors
Eva Poveda et al. J Antimicrob Chemother. 2007 Dec.
No abstract available
Similar articles
- Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, Ceresoli F, Gargiulo F, Manca N, Carosi G, Torti C. Lapadula G, et al. Antivir Ther. 2008;13(4):601-5. Antivir Ther. 2008. PMID: 18672539 - [Etravirine: genetic barrier and resistance development].
Llibre JM, Santos JR, Clotet B. Llibre JM, et al. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:32-9. doi: 10.1016/S0213-005X(09)73217-3. Enferm Infecc Microbiol Clin. 2009. PMID: 20116626 Review. Spanish. - Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
Cotte L, Trabaud MA, Tardy JC, Brochier C, Gilibert RP, Miailhes P, Trépo C, André P. Cotte L, et al. J Med Virol. 2009 Apr;81(4):672-7. doi: 10.1002/jmv.21461. J Med Virol. 2009. PMID: 19235860 - Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
Scott C, Grover D, Nelson M. Scott C, et al. AIDS. 2008 May 11;22(8):989-90. doi: 10.1097/QAD.0b013e3282fa75df. AIDS. 2008. PMID: 18453859 Clinical Trial. - HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
Ghosn J, Chaix ML, Delaugerre C. Ghosn J, et al. AIDS Rev. 2009 Jul-Sep;11(3):165-73. AIDS Rev. 2009. PMID: 19654858 Review.
Cited by
- Pharmacologic aspects of new antiretroviral drugs.
Long MC, King JR, Acosta EP. Long MC, et al. Curr HIV/AIDS Rep. 2009 Feb;6(1):43-50. doi: 10.1007/s11904-009-0007-y. Curr HIV/AIDS Rep. 2009. PMID: 19149996 Review. - Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.
Stellbrink HJ. Stellbrink HJ. Core Evid. 2010 Jun 15;4:149-58. doi: 10.2147/ce.s6009. Core Evid. 2010. PMID: 20694071 Free PMC article. - Pharmacologic aspects of new antiretroviral drugs.
Long MC, King JR, Acosta EP. Long MC, et al. Curr Infect Dis Rep. 2008 Nov;10(6):522-9. doi: 10.1007/s11908-008-0084-x. Curr Infect Dis Rep. 2008. PMID: 18945395 - Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.
da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. da Cunha J, et al. World J Virol. 2015 May 12;4(2):56-77. doi: 10.5501/wjv.v4.i2.56. World J Virol. 2015. PMID: 25964872 Free PMC article. Review. - Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults.
Harris M, Angel JB, Baril JG, Rachlis A, Trottier B. Harris M, et al. Can J Infect Dis Med Microbiol. 2009 Summer;20(2):e24-34. doi: 10.1155/2009/658125. Can J Infect Dis Med Microbiol. 2009. PMID: 20514155 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources